Skip to main content
AMGN
NASDAQ Life Sciences

Amgen re-adjudicates Tavneos trial data after safety issues; unit ordered to pay $20.2M

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$355.98
Mkt Cap
$191.704B
52W Low
$267.83
52W High
$391.29
52W Position info
33% above low
Off High info
9.0% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AMGN sits 33% above its 52-week low of $267.83.

Summary

Amgen is re-adjudicating pivotal trial data for its drug Tavneos, and its Teneobio unit was ordered to pay $20.2 million for patent infringement. The Tavneos re-adjudication follows a series of negative news, including an FDA link to 76 cases in March and warnings and prescribing halts in Japan in May due to adverse events and deaths. This re-evaluation suggests Amgen is seriously reviewing the drug's profile in light of ongoing safety concerns and regulatory scrutiny, which could impact its future market access or sales. The $20.2 million patent infringement verdict is financially insignificant for Amgen's nearly $192 billion market cap. Amgen will review the re-adjudication results for regulatory discussions.

At the time of this announcement, AMGN was trading at $355.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.7B. The 52-week trading range was $267.83 to $391.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $464.00 info
Change: -$13.40 (-3%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $464.00 info
Change: -$0.920 (-0.20%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $464.00 info
Change: +$1.00 (+0.22%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $464.00 info
Change: +$3.43 (+0.74%) info
Market Cap: $248.918B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $464.00 info
Change: +$15.21 (+3%) info
Market Cap: $248.918B info